Briefing
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
At 5 years, adjuvant nivolumab improved disease-free survival versus placebo (HR 0.74). In a post hoc Signatera analysis the disease-free survival HR was 0.35 if baseline ctDNA was detectable and 0.99 if it was not.
- Design: Evidence level 2
- Assay: Signatera
Annals of OncologyPubMed 41110694DOI 10.1016/j.annonc.2025.09.139